Barclays analyst Charles Pitman-King lowered the firm’s price target on Argenx (ARGX) to EUR 650 from EUR 710 and keeps an Overweight rating on the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx Receives Positive CHMP Opinion for VYVGART in CIDP Treatment
- Argenx announces CHMP opinion recommending approval of Vyvgart 1000mg
- Argenx Se’s Revenue Growth Potential Boosted by Vyvgart Hytrulo’s Market Impact and Increased Treatment Cycles
- Argenx price target lowered to EUR 680 from EUR 736 at BofA
- Argenx price target raised to $796 from $681 at Citi